These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 19814680

  • 1. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP, Yang YS, Yao CY, Peng CT.
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [Abstract] [Full Text] [Related]

  • 2. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 3. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M.
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [Abstract] [Full Text] [Related]

  • 5. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 6. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L.
    Clin Lymphoma Myeloma; 2009 Jul; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 9. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 10. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Jun; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 11. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P, Rose C.
    Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [Abstract] [Full Text] [Related]

  • 12. Myelodysplasia paranoia: iron as the new radon.
    Steensma DP.
    Leuk Res; 2009 Sep; 33(9):1158-63. PubMed ID: 19036443
    [Abstract] [Full Text] [Related]

  • 13. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 14. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J, Kurtin SE, Arnold L, Lindroos-Kolqvist P, Tinsley S.
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [Abstract] [Full Text] [Related]

  • 15. Treatment of iron overload in thalassemia.
    Cianciulli P.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [Abstract] [Full Text] [Related]

  • 16. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E, Hershko C, MDS Israel Group, Israel Society of Hematology.
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract] [Full Text] [Related]

  • 17. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 May; 33(5):283-6. PubMed ID: 19814673
    [Abstract] [Full Text] [Related]

  • 18. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 19. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S, Santini V, Musallam K, Taher A.
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [Abstract] [Full Text] [Related]

  • 20. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.